A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)

This study will consist of 2 stages. In stage 1, adult participants will be administered a
single dose of V114. After completion of a review of safety data from the adult cohort,
stage 2 of the study will enroll infants. Infants will receive a 4-dose schedule of either
an active comparator or 1 of 5 dose/adjuvant combinations of V114.

Inclusion Criteria:

Infants -Healthy and able to attend all scheduled visits.

Adults:

-Highly unlikely to conceive from vaccination through to 6 weeks after administration of
the vaccine.

Exclusion Criteria:

Infants and Adults

- Prior administration of any pneumococcal vaccine, any non-live vaccine within 14 days
or any live vaccine within 30 days

- History of invasive pneumococcal disease

- Known hypersensitivity to any vaccine component

- Received systemic corticosteroids within 14 days of first vaccination

- Known or suspected impairment of immune function

- Febrile illness within 72 hours before vaccination

- Received blood transfusion or blood products within 30 days. Infants

- Mother has documented human immunodeficiency virus or is hepatitis B surface antigen
positive

- Has asplenia or failure to thrive. Adults

- Is breastfeeding.